Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)
Chao Zhang(Harbin Medical University), Wen‐Zhao Zhong(Guangdong Academy of Medical Sciences)
Cited by 31
Related Papers
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
|Cell|2025|103
Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status
|Journal of Hematology & Oncology|2015|89
Expert consensus on treatment for stage III non‐small cell lung cancer
|Medicine Advances|2023|18
Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations
|The Innovation|2024|12